Blue Stream Laboratories Adds Capacity
News Nov 05, 2015
Blue Stream Laboratories is expanding into new office and lab space, adjacent to its current facility, to handle the continued growth of its biosimilars services. Last year, the company moved into new space in Woburn to double the capacity of its prior Cambridge facility.
Blue Stream will exhibit at Booth 8 at the Well Characterized Biologicals Conference from Nov. 9-10 at the Hyatt Regency Reston VA.
Having provided characterization services for 10 of the top biosimilar products in development, Blue Stream offers a complete suite of analytical solutions for biosimilar product development from initial product screening to biosimilar/originator comparability to comprehensive characterization including primary and secondary/tertiary structure, glycosylation/PTMs, and activity.
The biosimilar segment continues to perform well for the company. In 2014, Blue Stream recorded a 60 percent increase in revenue over the prior year, along with a 50 percent increase in facility size, and a 30 percent expansion of its research and development capabilities. This growth was significantly driven by Blue Stream’s biosimilars services.
“The market for biosimilars continues to grow, with consensus of reaching at least $20 billion within the next few years. Blue Stream has significant biosimilar expertise, and we continue to invest in the people, equipment and infrastructure to develop innovative methods, improve quality and extend our expertise,” said William Rash, VP, Sales and Marketing of Blue Stream Laboratories.
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Sequencing Shows How Evolution Can Undermine Bioprocess CommercializationNews
Rapid evolution can suppress the effect of pro-production genes in biochemical processes.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018
2nd International Conference on Food Science and Bioprocess Technology
Oct 01 - Oct 03, 2018